AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nuo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026
- Market cap
- $60.99M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
66.9%
Operating margin
-76.0%
Net margin
-75.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +142.7% | +209.1% | – | -11.7% | |
| Gross profit | +108.8% | +187.8% | – | -4.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 10.6% | 1134.6% | |
| Return on assets | – | -41.5% | -165.5% | |
| Current ratio | 2.33 | 0.24 | 1.06 | |
| Interest coverage | – | -7.8× | – | |
| Inventory turnover | – | – | 6.0× | |
| Capex to revenue | – | – | 8.3% | |
| Diluted shares | – | 27M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nuo Therapeutics generated $10.09M from operations and spent $496.95K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$10.09M
Used
$496.95K
Capital expenditure$496.95K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-75.8%
×Asset turnover2.18×
×Equity multiplier-6.85×
=Return on equity, FY20251134.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -75.8% | 2.18× | -6.85× | 1134.6% |
| FY2024 | -170.2% | 0.89× | 1.98× | -299.3% |
| FY2023 | -521.2% | 0.25× | 1.52× | -196.3% |
| FY2022 | -2825.6% | 0.05× | 1.51× | -212.6% |
| FY2019 | -817.4% | 0.23× | -0.97× | 185.1% |
| FY2018 | -112.5% | 1.14× | 5.99× | -769.2% |
| FY2017 | -2077.4% | 0.09× | 1.19× | -231.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.51M
- Cash generatingOperating cash flow above zero-$864.97K
- Return on assets improvedROA up on the prior year-123.7% → -211.2%
- Earnings backed by cashOperating cash flow above net income-$864.97K vs -$2.51M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.45 → 1.06
- No dilutionShare count did not rise45M → 47M
- Gross margin improvedGross margin up on the prior year77.82% → 66.94%
- More efficientAsset turnover rose0.73 → 2.79